Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for teens with painful skin condition: experimental drug povorcitinib under study

NCT ID NCT07213973

Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 10 times

Summary

This study tests an oral drug called povorcitinib in 40 adolescents aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful boils and tunnels. Over 54 weeks, researchers will check the drug's safety, how the body processes it, and whether it reduces skin abscesses and inflammation. Participants must have at least 5 active skin lesions and have not responded well to other treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Povorcitinib (a drug taken by mouth)
What this could lead to
If it works, this could point toward a new treatment option for teenagers with hidradenitis suppurativa, reducing painful skin abscesses and inflammation.
What could go wrong
This is an early phase 2 study with only 40 participants, so results may not apply to everyone. The drug may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥ 12 to \< 18 years at the time of informed consent/assent signing. * Body weight ≥ 30 kg at both screening and baseline visits. * Diagnosis of moderate to severe HS for at least 3 months prior to the screening visit. * Total abscess and inflammatory nodule count of at least 5 at both the screening and baseline visits. * HS lesions corresponding to refined Hurley Stage IB, IC, IIB, IIC, or III at both the screening and baseline visits. * Documented history of inadequate response to at least a 3-month course of at least 1 conventional systemic therapy (oral antibiotic or biologic drug) for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for treatment of their HS). * Agreement to use contraception. * Willing and able to comply with the study protocol and procedures. * Further inclusion criteria apply. Exclusion Criteria: * Presence of \> 20 draining tunnels (fistulas) at either the screening or baseline visit. * Women who are pregnant (or who are considering pregnancy) or breastfeeding. * Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator. * Laboratory values outside of the protocol-defined ranges. * Further exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa (HS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hidradenitis hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hidradenitis suppurativa (HS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    30 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • 3A Research Llc West Location

    NOT_YET_RECRUITING

    El Paso, Texas, 79902, United States

  • Advanced Medical Research Pc

    RECRUITING

    Sandy Springs, Georgia, 30328, United States

  • Bellaire Dermatology Associates Bda

    RECRUITING

    Bellaire, Texas, 77401, United States

  • Boeson Research Missoula 2825 Fort Missoula Rd

    RECRUITING

    Missoula, Montana, 59804, United States

  • Boston Childrens Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • Dermatology Skin Cancer Center Leawood

    RECRUITING

    Leawood, Kansas, 66211, United States

  • Dermcare Clinic

    RECRUITING

    Mississauga, Ontario, L4W 0C2, Canada

  • Endeavor Health Medical Group

    RECRUITING

    Skokie, Illinois, 60077, United States

  • Equity Medical

    RECRUITING

    Bowling Green, Kentucky, 42104, United States

  • Geisinger Medical Center

    RECRUITING

    Danville, Pennsylvania, 17822, United States

  • Johns Hopkins Univ Schl of Medicine

    RECRUITING

    Baltimore, Maryland, 21205, United States

  • Jordan Valley Dermatology Center

    RECRUITING

    South Jordan, Utah, 84095, United States

  • Medical Dermatology Specialists Phoenix

    RECRUITING

    Phoenix, Arizona, 85006, United States

  • Oakland Hills Dermatology Pc

    RECRUITING

    Auburn Hills, Michigan, 48326, United States

  • Revival Research Institute, Llc Troy

    RECRUITING

    Troy, Michigan, 48084, United States

  • Saguaro Dermatology

    RECRUITING

    Phoenix, Arizona, 85008, United States

  • Skin Oasis Dermatology

    NOT_YET_RECRUITING

    Gambrills, Maryland, 21054, United States

  • Skin Research of South Florida, Llc

    RECRUITING

    Miami, Florida, 33173, United States

  • Skincare Studio Dermatology Centre

    RECRUITING

    St. John's, A1E 1V4, Canada

  • Texas Dermatology Research Center

    RECRUITING

    Dallas, Texas, 75246, United States

  • The Hospital For Sick Children

    RECRUITING

    Toronto, Ontario, M5G 1X8, Canada

  • Trueblue Clinical Research

    RECRUITING

    Tampa, Florida, 33607, United States

  • Uconn Health

    RECRUITING

    Farmington, Connecticut, 06030, United States

  • University of Alabama At Birmingham

    RECRUITING

    Birmingham, Alabama, 35233, United States

  • University of Miami Miller School of Medicine

    RECRUITING

    Miami, Florida, 33136, United States

  • University of Missouri Kansas City

    NOT_YET_RECRUITING

    Kansas City, Missouri, 64108, United States

  • University of New Mexico Hospital

    RECRUITING

    Albuquerque, New Mexico, 87102, United States

  • Washington University

    RECRUITING

    St Louis, Missouri, 63110, United States

  • Wayne State University Physician Group Dermatology

    RECRUITING

    Detroit, Michigan, 48201, United States

  • York Dermatology Center

    RECRUITING

    Richmond Hill, Ontario, L4B 1L1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.